Cyclopharm Limited (ASX:CYC) is an Australian-based company manufacturing and selling nuclear medicine equipment, radiopharmaceuticals and related research and development services. The company specializes in imaging of lungs (Technegas system) and molecular imaging radiopharmaceuticals used in cancer, brain and cardiac imaging.
The acclaimed Cardiac Reseacher, Dr. Charles Antzelevitch, Executive Director and Director of Research of the Cardiac Research Institute (CRI) at the Masonic Medical Research Laboratory (MMRL), based in Utica, New York, presented the Keynote Lecture at the annual meeting of the Japanese Society of Electrocardiology.
Dr. Charles Antzelevitch, Executive Director and Director of Research of the Cardiac Research Institute (CRI) at Masonic Medical Research Laboratory (MMRL) in Utica, New York, presented the Keynote Lecture at the annual meeting of the Japanese Heart Rhythm Society. The symposium, attended by over 2,300 cardiologists, electrophysiologists and scientists from throughout the world was held in Yokohama, Japan, July 5-7, 2012.
Dr. Charles Antzelevitch, Executive Director and Director of Research of the Cardiac Research Institute (CRI) at Masonic Medical Research Laboratory (MMRL) and 4 members of the MMRL staff attended and presented 10 lectures and papers at the 33rd annual scientific sessions of the international Heart Rhythm Society (HRS). HRS2012, held on May 9-12, 2012 in Boston, MA. The event brought together over 13,000 cardiologists, electrophysiologists and other health care professionals from throughout the world.
Living Cell Technologies Limited's (ASX:LCT) (OTCQX:LVCLY) Medical Director, Emeritus Professor Robert Elliott, presented for the first time the results of pre-clinical trials of NTCELL therapy in non-human primate models of Parkinson's disease at BioPharma Asia 2012.
Mesoblast Limited (ASX:MSB) today announced that it has received clearance from the United States Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its proprietary adult stem cells for the treatment of Type 2 diabetes.
Asian Activities Report for December 16, 2011 includes: Asahi Glass Co., Ltd. (TYO:5201) will establish a new cathode materials production and sales site in China for lithium-ion batteries used in mobile devices and electronic vehicles; FUJIFILM Holdings Corporation (TYO:4901) has signed a definitive agreement to acquire all outstanding shares of SonoSite, Inc. (NASDAQ:SONO) for approximately US$995 million; Kobe Steel, Ltd. (TYO:5406) plans to increase the production capacity of its Chinese subsidiary which makes aluminum forgings for automotive suspensions; Eisai Co., Ltd. (TYO:4523) has received approval from Health Canada for Halaven(TM), a novel anticancer agent for the treatment of metastatic breast cancer.
